Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors

Study Purpose

A retrospective crosssectional observational study of the effects of oncological treatment and frequent general anesthesia on neuropsychological development, psychosocial functioning (in terms of anxiety, depression, peer relations, perceived cognitive functioning and potential trauma) and health related quality of life in children and young adults who were treated or screened for retinoblastoma.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Yes
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 6 Months - 35 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria Rb survivors and Rb risk carriers (age 8-35 years):

  • - Rb diagnosis, (main) treatment and follow-up of Rb patients and -survivors, or Rb screening took place at the Dutch Retinoblastoma Expertise Center of the Amsterdam University Medical Center, - Rb survivor or former Rb risk carriers is between 8 and 35 years old, - Average understanding of the Dutch language.
Inclusion Criteria parents of Rb patients, Rb survivors or Rb risk carriers (6 months
  • - 12 years): - Being a caregiver of a Rb survivor or Rb risk carrier that have been diagnosed and receive(d) (main) treatment and follow-up or screening at the Dutch Retinoblastoma Expertise Center of the Amsterdam University Medical Center, - The related Rb survivor or Rb risk carrier is < 12 years old, - Average understanding of the Dutch language.

Exclusion Criteria:

  • - Pre-existing documented developmental delay and/or severe cognitive impairments (IQ <70), - Having an active, uncontrolled psychiatric illness, - Rb diagnostic trajectory, treatment and follow-up at another hospital or before the founding of the Dutch Retinoblastoma Expertise Center in 1991.
With exception of Rb survivors (diagnosed >1991) who apart from treatment at the Dutch Retinoblastoma Center also required specialized treatment (such as radiation) at another center: they are illegible for inclusion.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT06227962
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Amsterdam University Medical Center
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Annette C. Moll, MD PhD
Principal Investigator Affiliation Amsterdam University Medical Center
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Enrolling by invitation
Countries Netherlands
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Retinoblastoma, Neurocognitive Dysfunction, Health-Related Behavior
Additional Details

Retinoblastoma (Rb) is the most common form of ocular cancer in children, with high survival rates in developed countries (>90%). Rb can develop unilateral (one eye affected, sometimes hereditary), or bilateral (both eyes, always hereditary). Children are usually diagnosed at a young age (<5 years) and are subjected to an intensive treatment and follow-up protocol immediately after. If Rb is diagnosed in early disease stages, eye-saving treatment could be provided, such as laser, cryo-, chemotherapy and/or radiotherapy -or a combination of these. When discovered in a later disease stage, enucleation (removing the eye) is often inevitable. Brothers and sisters or offspring of heredity Rb survivors that are at risk to develop Rb themselves (so called 'Rb risk carriers') will be screened according to the Dutch Rb Screening Protocol. The medical treatment and follow-up of Rb patients and screening of Rb risk carriers takes place under general anesthesia (GA) up to four or five years of age. At this age the brain is still developing and therefore extra vulnerable to iatrogenic damage, including neuropsychological complications. Immediate effects of the oncological treatment, as well as secondary effects due to multiple GA on cognitive development in Rb survivors is still understudied. Rb survivors report disease-related limitations in daily life and lower health related quality of life (HRQoL), which might be related to impaired cognitive functioning. Apart from possible immediate or secondary treatment effects, children with Rb are known to be experiencing psychosocial struggles, including anxiety and depression, declined participation and/or pediatric trauma, which may negatively affect HRQoL as well. Despite the impact on general wellbeing and HRQoL, the cognitive and emotional aspects of Rb are largely under addressed in pediatric care. It is important to gain insight in the cognitive development and psychosocial functioning from childhood into young adulthood of Rb survivors, as well psychosocial functioning of the parents in order to provide timely interventions, minimizing possible long-term consequences. It is hypothesized that extensive treatment and multiple GA is negatively associated with cognitive functioning, psychosocial functioning and HRQoL in Rb survivors and Rb risk carriers. Moreover, that psychological struggles and/or trauma strengthen these associations.

Arms & Interventions

Arms

: Retinoblastoma Survivors

Children and adults who survived retinoblastoma (8-35 years of age)

: Retinoblastoma Risk Carriers

Children and adults who (might) carry a genetic risk to develop retinoblastoma (8-35 years of age)

: Parents

Parents of Rb patients, Rb survivors, or Rb risk carriers (6 months-12 years of age)

Interventions

Diagnostic Test: - Neuropsychological assesment

Estimated intelligence (subtasks of Wechsler Intelligence Scale for Children - Fifth edition -Dutch version [WISC-V-NL] or Wechsler Adult Intelligence Scale - Forth edition - Dutch version [WAIS-IV-NL]); Vienna reaction time; Rey auditory verbal learning test; Word fluency; Beery-Buktenica Developmental Test of Visual-Motor Integration, 6th Edition; Test of Everyday Attention for Children (TEA-Ch), subtask Score!/ or Test of Everyday Attention (TEA), subtask Elevator task; Trail making test; Word-color interference test

Diagnostic Test: - Psychosocial functioning and quality of life (questionnaires)

Anxiety (PROMIS); Depression (PROMIS); Peer-interaction (PROMIS); Perceived neurocognitive functioning (PROMIS); Participation and activity (PAY-CY); Trauma (KJTS/PCL-5); Health related quality of life (PEDSQL)

Diagnostic Test: - Parental psychosocial functioning (questionnaires)

Anxiety (PROMIS); Depression (PROMIS); Distress Thermometer-Parents (DT-P); Trauma (PCL-5)

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Amsterdam University Medical Center, Amsterdam, Noord-Holland, Netherlands

Status

Address

Amsterdam University Medical Center

Amsterdam, Noord-Holland, 1081 HZ

Stay Informed & Connected